Effect of raloxifene on serum triglycerides in postmenopausal women: Influence of predisposing factors for hypertriglyceridemia

Clinical Therapeutics

Volumn 23, Issue 9, 2001, Pages 1552-1565

  Mosca, Lori ^a   Harper, Kristine ^b   Sarkar, Somnath ^b   O'Gorman, John ^b   Anderson, Pamela W ^b   Cox, David A ^b   Barrett Connor, Elizabeth ^c  

^a Department of Obstetrics Gynecology   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Hypertriglyceridemia; Lipids; Raloxifene; Selective estrogen receptor modulator; Triglycerides

Indexed keywords

ESTROGEN; PLACEBO; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TRIACYLGLYCEROL;

ADULT; AGE; AGED; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CIGARETTE SMOKING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE PREDISPOSITION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; HYPERTRIGLYCERIDEMIA; MAJOR CLINICAL STUDY; OSTEOPOROSIS; PANCREATITIS; POSTMENOPAUSE; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0034805446     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(01)80127-2     Document Type: Article

References (23)

1. Premarin® (conjugated estrogens)
2. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial
3. Lipoprotein, apolipoprotein, and lipolytic enzyme changes following estrogen administration in postmenopausal women
4. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
5. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women
6. Continuous combined and sequential estradiol and norethindrone acetate treatment of postmenopausal women: Effect of plasma lipoproteins in a two-year placebo-controlled trial
7. Is hypertriglyceridaemia an independent risk factor for coronary heart disease? The epidemiological evidence
8. Estrogen-induced pancreatitis: A caveat worth remembering
9. Severe hypertriglyceridemia and pancreatitis when estrogen replacement therapy is given to hypertriglyceridemia women
10. Hormone replacement therapy, diabetes and pancreatitis secondary to hypertriglyceridaemia
11. Therapy of hyperlipidemia
12. Clomiphene-induced severe hypertriglyceridemia and pancreatitis
13. Severe hypertriglyceridemia caused by tamoxifen-treatment after breast cancer surgery
14. Delayed severe hypertriglyceridemia from tamoxifen
15. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women
16. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial
17. The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: A randomized, controlled trial
18. The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation
19. Relevance of the reduction of triglycerides in the prevention of coronary heart disease
20. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III)
21. The potential of SERMs for reducing the risk of coronary heart disease
22. Design of the Women's Health Initiative clinical trial and observational study
23. Design and methods of the Raloxifene Use for the Heart (RUTH) study